Hydroxyethylrutoside

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Hydroxyethylrutosides (oxerutins, O-beta-hydroxyethyl-rutosides, HR or HER) are hydroxyethyl acetylations of rutoside. It may refer to :

Oxerutins are semisynthetic derivatives of plant constituents. Although they are closely related to the natural flavonoid rutin, hydroxyethylrutosides are not found in food. The only way to take them is in a supplement.[1]

Health benefits[edit]

Relvène (1967 French version), Venoruton (1962 Swiss version), and Paroven are mixtures of hydroxyethyl rutinosides. Hydroxyethylrutosides are used in the treatment of chronic venous insufficiency[2] and hypertensive microangiopathy.[3] Oxerutins works by reducing leakage from the small blood vessels (capillaries).[4]

Hydroxyethylrutosides have been used as an alternative to horse chestnut preparations (venostasin) containing aescin. Typical doses are in the order of 1,000 mg/day.[5]

Effects of hydroxyethylrutosides against adriamycin-induced toxicity have been investigated in rats.[6]

References[edit]

  1. ^ Oxerutins on healthlibrary.epnet.com
  2. ^ Frick, RW (2000). "Three treatments for chronic venous insufficiency: Escin, hydroxyethylrutoside, and Daflon". Angiology 51 (3): 197–205. doi:10.1177/000331970005100303. PMID 10744007. 
  3. ^ Incandela, L; Belcaro, G; Renton, S; Desanctis, MT; Cesarone, MR; Bavera, P; Ippolito, E; Bucci, M et al. (2002). "HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: A prospective, placebo-controlled, randomized trial". Journal of cardiovascular pharmacology and therapeutics. 7 Suppl 1: S7–S10. doi:10.1177/107424840200700103. PMID 12011966. 
  4. ^ Paroven on netdoctor.co.uk
  5. ^ The handbook of clinically tested herbal remedies, Volume 2 by Marilyn Barrett
  6. ^ Gulati, OP; Nordmann, H; Aellig, A; Maignan, MF; McGinness, J (1985). "Protective effects of O-(beta-hydroxyethyl)-rutosides (HR) against adriamycin-induced toxicity in rats". Archives internationales de pharmacodynamie et de therapie 273 (2): 323–34. PMID 4004421.